Sequence information
DRAVP ID DRAVPc067
Name Nirsevimab
Sequence
Molecular Formula C6494H10060N1708O2050S46
Condition/Disease respiratory syncytial virus (RSV) lower respiratory tract disease
Group Approved, Investigational
Type antibody
Description Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants. Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.
Active sequence/Structure
Comment
No comments found.
External Links
DrugBank Accession Number DB16258
Pubchem ID Not available
CHEMBL ID wu
UNII VRN8S9CW5V
CAS 1989556-22-0
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT00665951 | Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) (SURF) | HIV Infections | Completed | Phase 1 | Radboud University Medical Center |
| NCT01854762 | Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection (PregnantHIV) | HIV; Pregnancy | Terminated | Phase 2, Phase 3 | Fundação Bahiana de Infectologia |
| NCT04484935 | Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (MUSIC) | RSV Infection | Completed | Phase 2 | AstraZeneca |
